Omalizumab is a monoclonal antibody medication used for the treatment of certain allergic conditions. It is also known as brand name Xolair. Omalizumab is designed to target and inhibit the action of immunoglobulin E (IgE), a type of antibody involved in allergic reactions.
Key points:
Mechanism of Action: Omalizumab binds to the IgE antibodies circulating in the blood. This prevents IgE from attaching to immune cells and triggering the release of substances that contribute to allergic reactions.
Indications: Omalizumab is primarily used in the treatment of two conditions: allergic asthma and chronic idiopathic urticaria (chronic hives without a known cause).
Administration: Omalizumab is administered by subcutaneous injection, usually once every two to four weeks, depending on the specific condition being treated.
Monitoring and Side Effects: Regular monitoring is necessary during omalizumab treatment. Common side effects may include injection site reactions, headaches, viral infections, and upper respiratory tract infections.
Patient Eligibility: Eligibility for omalizumab is determined by healthcare providers based on the severity and nature of the allergic condition.
Cost and Insurance Coverage: Omalizumab can be an expensive medication, and insurance coverage may vary.